NCT04052971
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 60 Years (Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known, active, unstable CNS metastases and/or carcinomatous meningitis- see trial for details; Patients who had had prior treatment with more than 4 lines of systemic therapy for recurrent/metastatic disease
https://ClinicalTrials.gov/show/NCT04052971